43 completed. 43 Phase 2, 10 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 43 | Completed 43 |
| Phase 1 | 10 | Completed 10 |
| Phase 3 | 6 | Completed 6 |
Follow Scleroderma, Diffuse: new trials by email Literature Review of Scleroderma, Diffuse trials Research Report on Scleroderma, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open Label Extension Study of Brentuximab Vedotin in Early dcSSc Brentuximab vedotin - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 3 | 2024-02-14 | 2026-09-30 |
| Rituxmab Versus IL-6 in Treating ILD Rituximab, IL6 inhibitor - Interstitial Lung Disease, Scleroderma | Phase 2 / Phase 3 | Completed | Assiut University | 60 | 2021-12-01 | 2023-11-15 |
| Effects of FT011 in Systemic Sclerosis FT011, Placebo - Scleroderma, Systemic, Scleroderma, Diffuse | Phase 2 | Completed | Certa Therapeutics | 30 | 2021-07-19 | 2023-12-20 |
| Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis MT-7117, Placebo - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Completed | Tanabe Pharma America, Inc. | 76 | 2021-02-05 | 2025-12-30 |
| Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc) IgPro20, IgPro10 - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Completed | CSL Behring | 27 | 2019-09-19 | 2024-02-05 |
| Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis Brentuximab Vedotin - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 11 | 2019-05-07 | 2023-10-04 |
| Prednisolone in Early Diffuse Systemic Sclerosis Prednisolone 5 mg, Placebo oral capsule; From August 2020 'no additional treatment' - Systemic Sclerosis | Phase 2 | Completed | Prof. Ariane herrick | 35 | 2017-12-21 | 2021-07-30 |
| Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc) Tofacitinib, Placebo Oral Tablet - Systemic Sclerosis, Scleroderma | Phase 1 / Phase 2 | Completed | University of Michigan | 15 | 2017-09-25 | 2020-05-08 |
| Brentuximab Vedotin for Systemic Sclerosis Brentuximab Vedotin, Placebo - Diffuse Cutaneous Systemic Sclerosis, Scleroderma | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 17 | 2017-09-20 | 2026-05-05 |
| Riociguat in Scleroderma Associated Digital Ulcers Riociguat, Placebo - Scleroderma, Digital Ulcers | Phase 2 | Completed | Dinesh Khanna, MD, MS | 17 | 2016-09-01 | 2019-09-24 |
| Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers Diltiazem Gel 2%, Nitroglycerin Ointment 2%, Vaseline - Digital Ulcer of Scleroderma | Phase 2 | Completed | Mohammad Ali Nazarinia | 90 | 2016-06-01 | 2017-03-06 |
| Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis Bortezomib, Placebo, Mycophenolate mofetil - Lung Diseases, Interstitial, Systemic Sclerosis | Phase 2 | Completed | Northwestern University | 9 | 2016-03-01 | 2021-08-25 |
| Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis IVA337, Placebo - Scleroderma, Diffuse, Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Completed | Inventiva Pharma | 145 | 2015-10-29 | 2019-03-04 |
| Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial C-82 Topical Gel, 1%, C-82 Topical Gel, Placebo - Systemic Scleroderma | Phase 1 / Phase 2 | Completed | Prism Pharma Co., Ltd. | 17 | 2015-06-01 | 2017-08-17 |
| Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma atorvastatin, Placebo - Scleroderma | Phase 2 | Completed | Robyn T. Domsic, MD, MPH | 24 | 2015-02-01 | 2020-08-12 |
| Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Rituximab, Cyclophosphamide - Interstitial Lung Disease, Scleroderma | Phase 2 / Phase 3 | Completed | Royal Brompton & Harefield NHS Foundation Trust | 104 | 2014-11-01 | 2021-10-07 |
| Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis Alprostadil, Placebo - Raynaud's Phenomenon Secondary to Systemic Sclerosis | Phase 2 | Completed | NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) | 35 | 2014-11-01 | 2016-03-22 |
| Zibotentan Better Renal Scleroderma Outcome Study Zibotentan - Scleroderma, Scleroderma Renal Crisis | Phase 2 | Completed | University College, London | 27 | 2014-10-01 | 2017-10-31 |
| A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis Abatacept, Placebo - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Completed | Dinesh Khanna, MD, MS | 88 | 2014-09-01 | 2020-02-17 |
| Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS) Pirfenidone - Systemic Sclerosis | Phase 2 | Completed | Genentech, Inc. | 63 | 2013-10-01 | 2016-08-04 |
Showing 20 of 43. Sign in to see all of them.
Scleroderma, Systemic (24) · Lung Diseases, Interstitial (6) · Raynaud Disease (4) · Connective Tissue Diseases (3) · Pulmonary Fibrosis (3) · Pain (2) · Scleroderma, Limited (2) · Scleroderma, Localized (2) · Skin Diseases (2) · Acne Keloid (1) · Arthritis (1) · Arthritis, Rheumatoid (1) · Cicatrix (1) · Depression (1)
Skin and Connective Tissue Diseases (43) · Skin Diseases (41) · Connective Tissue Diseases (40) · Scleroderma, Systemic (19) · Pathological Conditions, Signs and Symptoms (10) · Lung Diseases (8) · Respiratory Tract Diseases (8) · Pathologic Processes (7) · Cardiovascular Diseases (4) · Embolism and Thrombosis (4) · Fibrosis (4) · Livedoid Vasculopathy (4) · Skin Diseases, Vascular (4) · Thrombosis (4) · Vascular Diseases (4)
Mycophenolic Acid (4) · Brentuximab Vedotin (3) · Rituximab (3) · Abatacept (2) · Bosentan (2) · Cyclophosphamide (2) · Imatinib Mesylate (2) · Alprostadil (1) · Antigens, Differentiation (1) · Atorvastatin (1) · Biopsy (1) · Bone Marrow Transplantation (1) · Bortezomib (1) · Cognitive Behavioral Therapy (1) · Dasatinib (1)
Actelion (2) · Dinesh Khanna, MD, MS (2) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (2) · University of Michigan (2) · Assistance Publique - Hôpitaux de Paris (1) · Assiut University (1) · Boston University (1) · Bristol-Myers Squibb (1) · CSL Behring (1) · Certa Therapeutics (1) · Federal University of São Paulo (1) · Fred Hutchinson Cancer Center (1) · Genentech, Inc. (1) · Genzyme, a Sanofi Company (1) · Hospital for Special Surgery, New York (1)
United States (27) · United Kingdom (9) · Canada (7) · Germany (6) · Italy (5) · Poland (5) · Spain (4) · France (3) · Australia (2) · Netherlands (2) · Switzerland (2) · Belgium (1) · Brazil (1) · Bulgaria (1) · Colombia (1)
Dinesh Khanna, MD (2) · Alexandre WS Silva, PhD (1) · Arnold E. Postlethwaite, MD (1) · Barbara Troupin, MD, MBA (1) · Christopher Denton, Professor (1) · Darren Kelly, PhD (1) · David Fox, MD (1) · Dinesh Khanna, MD, MS (1) · Dinesh Khanna, MD, MSc (1) · Donald P. Tashkin, MD (1) · Eliza Farmer Chakravarty (1)
PMID 11934971, PMID 15692967, PMID 16790698, PMID 17469162, PMID 17485423, PMID 17717203, PMID 17901414, PMID 18512816, PMID 18641099, PMID 19776222, PMID 19892673, PMID 19950289, PMID 20506355, PMID 20740615, PMID 23039171, PMID 23402088, PMID 23494072, PMID 23554239, PMID 24054756, PMID 24459219, PMID 25452309, PMID 25826322, PMID 26071192, PMID 27370878, PMID 27469583, PMID 28012804, PMID 28038680, PMID 28544580, PMID 28619061, PMID 29073351, PMID 29099620, PMID 29121645, PMID 30277862, PMID 30651141, PMID 31342624, PMID 31430058, PMID 31481106, PMID 31858338, PMID 33350170, PMID 33765691, PMID 33998674, PMID 34966900, PMID 35650639, PMID 35943798, PMID 36355434, PMID 36375479, PMID 36637209, PMID 38652570, PMID 39887900, PMID 39909490
1UM1AI110557 (1), 2018 (1), R01AI041721 (1), R01AR047219 (1), R01HL089758 (1), R01HL089901 (1), R21AR066305 (1), R34HL122558 (1), UM1AI109565 (1)